Michał Ziołkowski

Michał Ziołkowski

Auto-generated profile, based on publicly available information

Michał Ziołkowski

Department of Cardiology and Clinical Pharmacology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, 85-168 Bydgoszcz, Poland

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ŁLŁukasz Ledziński
Łukasz Ledziński
GGGrzegorz Grześk
Grzegorz Grześk
MZMichał Ziołkowski
Michał Ziołkowski
MWMarcin Waligóra
Marcin Waligóra
Marcin Kurzyna, MD, PhD, FESCMarcin Kurzyna, MD, PhD, FESC
Marcin Kurzyna, MD, PhD, FESC
Grzegorz KopecGrzegorz Kopec
Grzegorz Kopec
Background/Objectives: Pulmonary arterial hypertension (PAH) is a complex cardiovascular disease with a high burden of morbidity and mortality. Although several risk prediction models have been proposed, the exact significance of distinct clinical parameters in predicting survival in PAH remains unclear. It is important to emphasize that this study does not aim to validate or contradict existing clinical risk assessment calculators provided by the ESC or other scientific societies. Instead, the goal of this research is to identify and rank clinical parameters according to their importance in predicting mortality in PAH patients using machine learning techniques. Methods: Using the Database of Pulmonary Hypertension in the Polish population (BNP-PL) registry, 1755 adult patients with PAH were selected. Feature engineering was conducted using domain knowledge, guided by European Society of Cardiology (ESC) recommendations. Features were reduced using LASSO regression and sequential feature elimination algorithms. A classification model was built using the XGBoost algorithm, utilizing 17 features. The model was tested on a preselected subset of the BNP-PL data. The Shapley Additive Explanations (SHAP) method was used to explain the model’s predictions and to rank feature importance. Results: The model achieved satisfactory results across evaluated metrics, including an area under the curve of 0.767, accuracy of 0.738, specificity of 0.733, and sensitivity of 0.800. SHAP values effectively ranked the features, corroborating the significance of parameters present in the ESC risk stratification tables. Furthermore, local interpretation of results using SHAP enabled individualized assessment of feature importance, enhancing clinical applicability. Conclusions: The proposed artificial intelligence-based model demonstrates satisfactory predictive capability, highlighting the potential of machine learning techniques to support more personalized approaches to the management of PAH patients. This approach offers complementary insights into traditional risk assessment methods, providing clinicians with a novel tool for individualized risk evaluation and decision-making.

30 November 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JBJoanna Boinska
Joanna Boinska
MKMarek Koziński
Marek Koziński
MKMichal Kasprzak
Michal Kasprzak
MZMichał Ziołkowski
Michał Ziołkowski
JKJacek Kubica
Jacek Kubica
DRDanuta Rość
Danuta Rość
There is limited information about diurnal changes in fibrinolysis parameters after acute myocardial infarction (AMI) and their relationship with on-treatment platelet reactivity. The aim of this study was to assess tissue plasminogen activator (t-PA), plasminogen activator inhibitor type-1 (PAI-1), α2-antiplasmin (α2-AP) activity, and plasmin–antiplasmin (PAP) complexes in 30 AMI patients taking dual antiplatelet therapy (DAPT), i.e., acetylsalicylic acid and clopidogrel. Fibrinolytic parameters were assessed at four time points (6 a.m., 10 a.m., 2 p.m., and 7 p.m.) on the third day after AMI using immunoenzymatic methods. Moreover, platelet reactivity was measured using multiple-electrode aggregometry, to assess potential differences in fibrinolytic parameters in low/high on-aspirin platelet reactivity and low/high on-clopidogrel platelet reactivity subgroups of patients. We detected significant diurnal oscillations in t-PA and PAI-1 levels in the whole study group. However, PAP complexes and α2-AP activity were similar at the analyzed time points. Our study reveals a potential impact of DAPT on the time course of fibrinolytic parameters, especially regarding clopidogrel. We suggest the presence of diurnal variations in t-PA and PAI-1 concentrations in AMI patients, with the highest levels midmorning, regardless of platelet reactivity. Significantly elevated levels of PAI-1 during the evening hours in clopidogrel-resistant patients may increase the risk of thrombosis.

28 February 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ŁLŁukasz Ledziński
Łukasz Ledziński
GGGrzegorz Grześk
Grzegorz Grześk
MZMichał Ziołkowski
Michał Ziołkowski
MWMarcin Waligóra
Marcin Waligóra
Marcin Kurzyna, MD, PhD, FESCMarcin Kurzyna, MD, PhD, FESC
Marcin Kurzyna, MD, PhD, FESC
Grzegorz KopecGrzegorz Kopec
Grzegorz Kopec
The present Reply addresses the commentary by Pagnoni et al. on our recent study exploring explainable artificial intelligence (AI) for mortality risk prediction in pulmonary arterial hypertension (PAH). We acknowledge the importance of several key issues raised by the authors, including endpoint selection, calibration, decision thresholds, and external validation, all of which are central to translating AI-based prognostic models into clinical practice. Our original endpoint, defined as death by the next follow-up visit, was driven by the structure of nationwide registry data and reflects real-world clinical workflows, although we recognize the advantages of predefined time horizons and time-to-event approaches for future analyses. We discuss the trade-off between sensitivity and precision, emphasizing our deliberate prioritization of minimizing false-negative classifications in high-risk patients, while acknowledging the need for structured clinical pathways to manage false-positive results. We further address calibration and threshold selection, underscoring the necessity of additional clinical studies to support intervention-oriented recommendations. The role of phenotypic determinants and modifiable risk factors in enhancing personalization is highlighted as a key direction for future model development. We reaffirm the value of SHAP-based explainability for improving model transparency, while recognizing the need for continued refinement and clinical validation. Finally, we emphasize the strengths and challenges inherent to registry-based analyses, the importance of external validation, and the need for methodologically sound comparisons with established risk calculators. Overall, this exchange underscores the critical role of interdisciplinary collaboration in advancing clinically actionable and interpretable AI solutions for PAH.